Company intelligence / Profile preview

Wellesley Pharmaceuticals

Newtown, Pennsylvania, United Stateswellesleypharma.com ↗

Ownership: Private
Development stage: Phase 2

Overview

Wellesley Pharmaceuticals developed Nocturol/Paxerol™, an oral combination therapy targeting nocturia. The lead candidate completed Phase 2 trials showing reduction in nighttime bathroom visits. The product has been licensed to a major pharmaceutical partner for further development and commercialization. Patent protection exists in the US and several international markets. A lower-dose version for pediatric bedwetting has patent pending status

Therapeutic areas: PsychiatryNephrology
Modalities: Small molecules (combination drug—acetaminophen and ibuprofen)
Industry: Biotech

Drug pipeline

1 asset

Paxerol

Partnerships

Licensed patents/product to an unnamed "big pharma" firm for late-stage clinical development and commercialization.

Beyond the preview

Go deeper on Wellesley Pharmaceuticals.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Wellesley Pharmaceuticals.

Explore the full profile